← All trials
NCT05806164
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2023
- Primary completion
- Jul 15, 2026
- Completion date
- Jul 15, 2027
- First posted
- Apr 10, 2023
- Last posted
- Aug 3, 2023
- Enrollment
- 432
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Brown UniversityLead sponsor
- Brown UniversityCollaborator
- Brown UniversityOverall official - principal investigator
- Brown UniversityReponsible party - principal investigator
- Howard UniversityCollaborator
- University of New MexicoCollaborator
- University of New MexicoOverall official - principal investigator
- University of California, San DiegoCollaborator
- University of Alabama, BirminghamCollaborator
- Patient-Centered Outcomes Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.